Agilent Expands Altura Portfolio with New Biotherapeutic Analysis Columns
Event summary
- Agilent introduced new Altura size exclusion chromatography (SEC) and PLRP-S columns for biopharmaceutical analysis.
- The columns support critical workflows for peptides, proteins, oligonucleotides, and conjugated therapeutics.
- Altura SEC columns offer up to double the sensitivity in aggregate analysis of GLP-1 peptides compared to competitors.
- The new products are part of Agilent's broader portfolio of inert liquid chromatography solutions.
The big picture
Agilent's expansion of its Altura HPLC column portfolio underscores the growing demand for high-performance, inert separation technologies in biopharmaceutical development. As biotherapeutic modalities become more complex, the need for reliable and accurate analytical tools is critical. This move positions Agilent to capture a larger share of the biopharma analytics market, particularly as laboratories seek integrated solutions that improve workflow efficiency and data consistency.
What we're watching
- Market Adoption
- How quickly biopharmaceutical companies will integrate the new Altura columns into their workflows.
- Competitive Response
- Whether competitors will introduce similar inert technology solutions to challenge Agilent's offerings.
- Technological Advancements
- The pace at which Agilent can further enhance the performance of its Altura portfolio.
Related topics